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Summary  
As we age, most of us experience a certain degree of cognitive decline. In most cases, this 
decline is gradual. However, in some cases, cognitive impairment is so severe it can be 
classified as dementia and this impacts greatly on activities of daily living. Alzheimer’s 
disease (AD), the most common form of dementia, has been linked to a reduction in estrogen 
(E) levels that come with aging. More specifically, many researchers have hypothesized that 
E, and hence E replacement via Hormone Therapy (HT), could protect against cognitive 
decline in women. However, recent randomised controlled trials (RCTs) did not reflect this. 
In fact, some reports showed that HT could be detrimental on cognition in older 
postmenopausal women. The most publicised of these has been the Women’s Health Initiative 
Memory Study (WHIMS). However, studies have yielded conflicting results and conclusions. 
The reasons for this may be due to a number of factors, such as the age of participants, the 
time of HT onset (‘window of opportunity’ theory), type of treatment, type of menopause 
(surgical or natural) and, possibly, genetic risk factors. We performed quantitative and 
qualitative meta-analyses and reviewed each of these factors in detail. The future may lie in 
combining these factors in order to fully understand the potential mechanisms behind E and 
its effect on cognition. 
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Introduction 
We live in a world where people have increasingly longer, but not necessarily healthier lives. 
As we age, and brain cells gradually demise, there is a discernible decline in some cognitive 
functions, such as verbal memory, speed of information processing and complex spatial and 
verbal skills. The hippocampus, which is particularly important to memory function, loses 
approximately 5 percent of its volume every decade after the age of 65 years [1]. In 
pathological cognitive aging, such as dementia, people experience a more pronounced decline 
of cognitive functions, which impacts on activities of daily living. The most common form of 
dementia is Alzheimer’s disease (AD). AD is a progressive dementia that initially usually 
manifests with memory deficiencies, one of its earlier and more pronounced symptoms, which 
are later followed by other cognitive deficits [2]. The speed and degree of cognitive decline 
shows great variability between individuals, ranging from “successful” aging to having more 
severe cognitive problems, such as dementia [3]. What determines this variability is not 
certain, but women may have a greater risk of developing AD than men [4]. This could be 
attributed to the fact that women reach an older age than men, and AD shows a greater 
incidence with age. However, the age-specific incidence of AD was also reported to be higher 
in women than in men [5]. This distinction could be linked to the more pronounced deficiency 
in steroid hormones, such as estrogen (E), in women after the menopause. Because of its 
biological plausibility to protect the brain, deficiency in E after the menopause has been 
suggested as a potentially important factor in the development of dementia. Therefore, it was 
believed that Hormone Therapy (HT) would be a beneficial intervention for treating or 
preventing dementia in older women [6,7]. 
 
1. Historical Background  
The relationship between sex hormones (both endogenous and via HT) and cognitive function 
has been under extensive investigation over the last 3 decades. Results of many animal and 
cell culture studies have repeatedly shown potential protective effects of E on the brain. For 
instance, synaptic plasticity was shown to be enhanced through binding of E to its receptors in 
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the hippocampus and nucleus basalis of Meynert, areas both implicated in AD [8].  In animal 
models, E has been found to increase dendritic density in the hippocampus, which has the 
highest concentration of E receptors [9]. In affected AD brains, the hippocampal region is 
severely afflicted, suggesting that the biological effects of E in this area of the brain could 
perhaps preserve cognitive functioning by having an impact on cognitive decline prior to the 
onset of AD. It has been found that E use preserves regional cerebral metabolism, protecting 
against metabolic decline in postmenopausal women, again especially in the areas of the brain 
found to be adversely affected by AD [10]. Detailed reviews of the possible effects of E in 
protecting the brain are already available [11,12]. In fact, it was stated that there are almost 
innumerable biological reasons why E could be protective against both benign memory loss 
and senile dementia [13]. 
 
The nineties showed great optimism about the benefits of E therapy in the treatment of AD, 
encouraged by an increasing number of positive observational studies and a number of small 
treatment trials, which provided evidence supporting the potentially biological beneficial 
effects of E. The basic biological mechanisms, as well as the supportive evidence from human 
observational studies, have been extensively reviewed [14,15,16,17]. The theoretical basis 
behind the idea that E could protect against AD was summed up as follows [18]: 
(i) there is a positive relationship between AD and decreasing E levels after menopause 
(ii) a sudden earlier loss of gonadal function seen in postmenopausal women compared to 
men is associated with an increased prevalence of AD in women 
(iii) there is generally decreased incidence and delay in the onset of AD in observational 
studies of women using HT after the menopause [18] 
While these arguments follow a logical system, they are, unfortunately, not always supported 
by research. Firstly, in contrast to initial findings, several well controlled observational 
studies actually reported higher levels of E in women with AD compared with controls (see 
for a review: [19]). Secondly, in contrast to European and Asian studies, observational studies 
in the US did not find increased incidence of AD in elderly women as compared to age-
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matched men (see [20]). Lastly, more recent, but also several earlier observational studies did 
not show protective associations of HT use against AD (see for an overview [19]). 
Importantly, several sources of bias (e.g. healthy user bias, recall bias) exist in these 
observational studies, which also limits their predictive value.  
 
These contra arguments are thus concerned with observational studies. However, there 
remains an abundance of evidence from in vitro and in vivo studies suggesting that E could 
act favourably upon almost all mechanisms known to be affected in cognitive decline and AD 
[21]. Prior to recent findings, the idea that HT could potentially reduce the risk for dementia 
in women was widely credited and accepted. Well controlled treatment studies ultimately 
provide the most compelling evidence. Most of the early treatment studies showed favourable 
effects of HT, in line with biological plausibility studies[15]. However, several of the initial 
treatment trials had methodological problems (size, statistical analyses etc), which had 
already earlier lead to scepticism about their results [22]. In addition, many treatment studies 
done in recent years have yielded opposing results. For example, several large well controlled 
recent randomized controlled trials (RCT) [23,24,25] showed that HT did not prevent 
cognitive decline and did not improve cognitive abilities in postmenopausal women with or 
without dementia. 
 
Women’s Health Initiative Memory Study 
The largest and best known of these RCTs to date has been the Women’s Health Initiative-
Memory Study (WHIMS) [26]. The WHIMS was a large multi-centre, randomised, double-
blind, placebo-controlled trial in which a subgroup of several thousand women from the 
Women’s Health Initiative (WHI) study were assessed for the effects of HT on dementia and 
mild cognitive impairment. Participants were aged 65 or older (and were thus all 
postmenopausal), received conjugated equine estrogens (CEE) plus medroxyprogesterone 
(MPA) vs. placebo [27], or continuous unopposed CEE vs. placebo [28]. The combined trial 
arm was discontinued in 2002 after concerns arose regarding its safety (mainly an increased 
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risk in breast cancer). The CEE and MPA trial found, contrary to the earlier wealth of 
scientific evidence, which hailed HT as having a positive influence on cognitive function, that 
the widely used CEEs (both Premarin and Prempro) were detrimental to neurocognitive health 
and increased the risk for dementia [26,27]. Several scientists concurred with the WHIMS 
authors that HT should not be recommended as an effective preventive treatment against 
dementia [29]. However, a smaller subset of WHIMS participants receiving combined 
treatment (n=1417) showed some positive effects on visual memory, but only after 3 years of 
treatment [30]. This, once again, shows the variable results of HT and cognition studies. 
  
In February 2004, the estrogen-only (CEE) arm of WHIMS (WHI) was also discontinued due 
to an unacceptable increased risk of stroke with treatment. The results were published in April 
of the same year [28,31]. Similar to WHIMS findings of CEE and MPA trial, it reported an 
increased risk in dementia onset, although it was of a smaller magnitude[31]. Meta-analyses 
on cognitive function (measured with the modified mental status examination) show an 
overall effect in favour of placebo (z=2.04, p<0.05, mean difference -0.15, 95% Confidence 
Interval or CI=-0.29 to -0.01 for combined trail and z=2.49, p<0.0005, mean difference -0.38, 
95% CI=-0.60 to -0.17 for CEE alone). However, individual analyses per year show 
inconsistencies in risk over time in both studies. While the effect of the combined trial only 
showed a significant difference in favour of the placebo group at year 4 (z=2.26, p<0.05), this 
was seen after CEE alone only at year 1 (z=2.25, p<0.05) when taking into account the 
number of women who dropped-out each year. 
 
The results of WHIMS are a far cry from earlier positive reports of the potential effects of 
HT. It has been argued that there may be some important reasons for the negative results 
found in WHIMS, as well as some rational behind the general discrepancy seen in the field as 
a whole. It has been suggested that differences in the age of participants, (resulting in the 
‘window of opportunity’ theory [32]), type, form and route of treatment, and type of 
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menopause that participants had undergone (surgical or menopausal) are mostly responsible 
for the lack of uniformity in results. These factors shall be addressed in more detail below.                                       
 
      2.     Factors explaining the variability in outcomes between studies 
2.1 Age 
Some researchers have argued that the negative results found in WHIMS were partially due to 
the age of participants [33]. The advanced age (65+ years of age) and obesity of participants 
in this study was deemed not representative of the population that HT is aimed at. The 
majority of participants may have been beyond the scope of help in averting most of the 
negative outcomes (stroke, dementia). However, that would not explain the negative effects 
seen in the WHIMS. Another review [34] reported little support for beneficial effects of E 
(both alone and in combination with Progesterone – P) in women older than 65 years of age, 
and it was noted that potentially beneficial effects on specific cognitive functions were mainly 
seen in younger and more recently menopausal women. In a recent study, the relation between 
HT use and a lowered risk of developing AD in 971 postmenopausal women showed a 
protective association, but only in women of the youngest age tertile (50-63 years) [35]. This 
finding is in line with animal studies suggesting protective brain effects in young, but not 
older animals [36].  
 
2.2  ‘Window of Opportunity’ theory 
Several authors have thus suggested that there is a critical period for HT treatment in order to 
obtain positive effects on the brain. It is hypothesized that initiating or continuing HT beyond 
this critical period would have little effect on the brain and cognitive function [32]. The 
‘window of opportunity’ theory suggests that there is a critical time for the initiation of HT 
and could explain why no protective effects were seen in WHIMS. Results from animal 
studies suggest that the longer the delay between ovariectomy and onset of treatment, the less 
chance there is of detecting the favourable effects of HT on the brain [37]. 
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However, the strongest argument against this theory is that in RCTs of women with AD, both 
Premarin and transdermal estradiol (E2) were seen to have similarly positive effects, but only 
for 2-3 months [38]. These women with AD (of whom the majority would be over 65 years of 
age) were at least 15 to 20 years older than the recently menopausal women (with a mean age 
of 48 years of age) in the successful E2 trails described in another meta-analysis [19]. This 
meta-analysis suggested that positive effects of E2 in women without dementia were also 
time-limited, resulting in an increase in memory, accuracy and abstract reasoning functions, 
but again only up to 2-3 months. For both older and younger, more recently menopausal 
women, a possible reversal of positive effects was seen on some cognitive functions after one 
year of treatment. Therefore, it seemed more likely that positive effects, if they were found, 
are only short lived, regardless of age. These findings also tie in with the WHIMS data. It has 
often been suggested that effects of HT are limited to particular aspects of cognitive function 
which could be an alternative reason for some studies not finding any effects. For this review, 
we performed quantitative and qualitative meta-analyses using Revman software provided by 
the Cochrane library standardized review system, employing both their inclusion criteria and 
their statistical methods (update) [39]. See textbox and Table 1 and 2 
TEXTBOX  Meta-analyses of studies investigating the effects of HT on different 
aspects of cognitive function 
Verbal memory 
Table 1 and 2 show that of all studies, only 23 of the tests used (22%, out of 106 cognitive tests used 
over all studies) showed a positive effect, while 3 tests had a negative result. Of these positive effects, a 
quarter of tests used (n=6) reflected a positive effect of HT on verbal memory, but 12 verbal memory 
tests used could not show this and one study (on WHIMS data, see below) showed that CEE with MPA 
had a negative effect on verbal memory over a longer period of several years. 
Qualitative analyses using Table 1 shows that the positive effects on memory were only seen in four 
studies after treatment for a short duration of time (2-3 months). This was seen in a study using oral 
estradiol (E2) in younger postmenopausal women reporting insomnia (of an average age of 49 years of 
age) [40] and in studies using bolus injections of E2 in surgically menopausal women aged on average 
48 [41]; 45 [42]; and 47 [43] years of age. In contrast, several other studies (using transdermal E2 in 
younger women with an average of 57 years of age)[44] and transdermal or oral E2 in older women of 
an average age of 71 years old [46] and 74 years old [45] respectively; 70 years old with oral E2 [25]; 
69 years old with  transdermal E2 [47]) did not reflect these effects. Studies with CEE did not report 
positive effects on verbal memory in younger (51 years old) [48] or older (82 years old) [49] women, 
although one study (sub-study of the WHIMS) reported a negative effect of CEE and MPA on verbal 
memory in older women (74 years old) [30]. These qualitative analyses were done using the reports of 
the investigators.  
Quantitative analyses showed only an overall positive effect on one test, the verbal paired associates 
immediate recall (z=2.40, p<0.05 effect size 1.02 95% CI=0.19-1.85)[41,42], but not on the delayed 
recall or recall of word lists or stories or on Verbal Fluency (which also tests language and executive 
functions). These analyses may be limited as standard deviations (SD) of the mean difference often had 
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to be recalculated which, in smaller studies, could lead to an overestimate of the SD, making these 
analyses vulnerable to type II error. However, it does indicate that effects, if present, are small. 
Visual memory 
On visual memory tests (where verbalization may occur), positive effects of E2 were seen on the 
memory of faces in women of 74 years of age (after 5 months of oral E2) [45]; and on picture recall 
and visual paired associates in women 65 of years of age (3 weeks E2 transdermal) [50] but also after 
CEE and MPA on figure recall after 3 years in women of 74 years of age [30]. Fifteen studies reported 
no effects on visual memory regardless of age or type of treatment [25,40,41,42,44,46,47,48,51,52,53]. 
Differences in tests could explain the differences between studies, but quantitative meta-analyses 
showed no significance for tests of heterogeneity. These analyses also revealed no overall significant 
effect of HT on visual memory. Traditionally, effects of E have been thought to be most apparent on 
verbal memory tests [54].  
Speeded tests 
However, several studies reported positive effects of HT on speed of information processing (found on 
a third of all tests used in studies). This was the case in 5 studies using transdermal E2 with women 65 
years of age [50]; transdermal E2 with women aged 57 years old [44]; oral E2 with women aged 57 
years [55]; transdermal E2 with women aged 71 years [46]; bolus E2 with women aged 45 years [43], 
although several other tests used in studies with transdermal E2 [44,46,47,50,53] could not reflect this. 
Three studies using CEE [56,57,58] reported no effects on speeded tests. 
Quantitative meta-analyses found overall trends on simple tests (TMT-A and SRT, p=0.06) and more 
complex tests (TMT-B and Stroop, p=0.10). Surprisingly, for simple speed, these analyses involved 
studies with CEE and MPA for 9 months1 [49] and transdermal E2 for 24 weeks [46], both in older 
women. For complex speed positive effects were seen in quantitative meta-analyses, again with CEE 
and MPA [49], after transdermal E2 in older women for two weeks [47] and three weeks [50] and also 
after oral E2 in younger women for a duration of ten weeks [44]. Other tests, such as CRT, Digit 
Vigilance and Digit Symbol Substitution Test, were not affected by HT. 
Other 
Several other tests showed positive effects, but only after bolus injections of E2 in surgical menopausal 
women [43] on executive functions (abstract reasoning) and accuracy or after oral E2 in symptomatic 
young women [55]. Meta-analyses showed that there was not an overall significant effect of HT on 
these types of tests (p=.14; p=.16) Three studies showed no overall effect of HT on the MMSE or 
CAMCOG [25,45; Greenspan 2005] and negative effects were found twice after HT on the modified 
3MSE in WHIMS[27,8]. However, in sub- analyses [25], elderly women without stroke who had a 
normal MMSE (28-30) were found to significant less decline after E2 treatment compared to placebo 
after 3 years (z=2.37, p<0.005). 
 
-insert Tables 1 and 2- 
Summarizing the text box findings in Table 2 shows that E2 given orally or as a bolus 
injection was mainly effective in improving verbal memory for very recently menopausal 
younger symptomatic or surgically menopausal women, but this was only tested up to 3 
months. Several earlier studies suggested that effects of E2 on memory actually may reverse 
after 6 months to a year [19]. The positive effect was also small, as it only held up in meta-
analyses for one aspect of one test. For visual memory, effects were not clear. We saw some 
positive effects on visual memory after transdermal E2 and CEE and MPA, but only in older 
women. This may argue against the ‘window of opportunity’ theory. Similarly, the results for 
                                                 
1but the authors [49] did not report our finding having used the slope over 3 time points for analyses, but not the mean 
difference, as we did 
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speeded tests indicated that the successful type of E treatment could depend on age: the 
younger symptomatic group seemed to profit most from an oral or bolus injection of E2, 
while the older women could possibly profit from transdermal E2 and CEE and MPA. The 
only significant effect on accuracy and abstract reasoning was found in one study of 
surgically menopausal women after a bolus injection. Adding P did not seem to alter results 
substantially (see also [19]). None of the meta-analyses showed significant heterogeneity and 
the more conservative standardized mean differences with random effects (rather than 
weighted mean differences with fixed effects) were used throughout. 
 
These analyses thus showed, as stated earlier [15], that possibly not all cognitive tests may be 
equally sensitive to HT and that different treatments may show different cognitive effects, 
which may also depend on age. Of course, the WHIMS, as the largest study which included 
older women, reported that women who used CEE and MPA after 2 years and CEE alone 
after 3 years had less improvement on the 3MSE and a greater risk of dementia, but the 
effects were small. As also mentioned, while a decrease in verbal memory was seen, the 
WHIMS sub-study actually reported improvements in visual memory after combined HT at 
this time point.   
 
2.3 Treatment Form / Route and duration 
Whether HT given for a longer period of time to older women could actually increase 
dementia risk was reviewed by others and several possible mechanisms for this relation were 
suggested [59]. These mechanisms were based on the theory that a longer life span, a lower 
prevalence of vascular dementia, and lower levels of testosterone (T) in women may 
contribute to the higher prevalence of AD. The mechanisms, that may have been active in 
WHIMS and potentially responsible for an increase in dementia, could be:  
1) use of MPA and Estrone (E1), which is a major metabolite of CEE, which may have 
different effects on neuronal and cerebrovascular function than P and E2 (the most potent E);  
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2) a greater risk of stroke (caused by the use of MPA [60] or through accidental inclusion of 
those at risk for stroke) leading to dementia;  
3) and, lastly, a decrease of bioavailable T (through the increase in sex hormone binding 
globulin or SHBG, which CEE induces to a greater extend than E2 does [61]. T can, directly 
or through conversion into E2, protect against AD[62]. 
 
Arguments against these mechanisms are the following. Firstly, as we saw in the meta-
analyses, while on verbal memory only E2 had positive effects in relatively younger 
postmenopausal symptomatic women, small positive effects of CEE with or without MPA 
were seen on some cognitive tests, but only in older women. In addition, exclusion of women 
with stroke, in the CEE alone or CEE with MPA trial, did not substantially alter the negative 
effect of HT on the overall improvement on the 3MSE [28]. Lastly, while SHBG may 
increase with CEE, so would the amount of E when treating with CEE. The role of 
bioavailable T and E2 (and the ratio of T:E2) on cognitive function in elderly women is not 
well understood and requires further investigation. It is unclear whether CEE metabolites 
would have worse effects than E2, but brain E receptors are more sensitive to E2 than E1 
[63]. However, in a recent RCT focusing on Event Related Potentials in women with an 
average age of 60 years, a positive effect of CEE was found [64]. The results showed a 
shortening of P300 latency which is consistent with normalisation of cognitive function. This 
result casts further uncertainty into the understanding of the role of CEE in cognitive 
treatment. One observational study reported that higher E1 levels were associated with 
detrimental effects on cognition. In the Study of Osteoporotic Fractures [65], women in the 
highest E1 quartile showed worse scores than women in the lower E1 quartiles on two 
cognitive tests. In contrast with this, the majority of observational studies showed a protective 
association (although tainted by several potential confounds, such as the healthy user bias 
[19]). Most women in the U.S.-based studies would have used CEE (in the form of Prempro 
and Premarin) and would have thus been exposed to E1 metabolites. Lastly, as mentioned 
above, CEE (similar to transdermal E2) has also shown positive effects on cognition in 
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women with dementia [39] and, as our most recent meta-analyses suggest, also on some tests 
in older women without dementia.  
 
Taken together, these findings suggest that as well as the form of HT, the route of 
administration may also be of importance and may depend on the age of the women. Where 
oral and bolus injections of E2 with or without P may be more suitable for relatively recently 
menopausal women, transdermal E2 and possible CEE could be more suitable for older 
women. However, it is not clear whether and which positive effects, if they exist at all, 
reverse after longer periods of usage.  
 
2.4 Surgical Menopause 
Our quantitative meta-analyses of women without dementia [39] and the current updated 
meta-analyses analyses indicated that significant effects of HT were strongest in women who 
had undergone for surgical menopause. A significant drop in cognitive function after 
ovariectomy has been shown [43,66,67]. In contrast, researchers could not find any evidence 
suggesting that natural menopause causes a drop in cognitive functions [68]. Therefore, one 
conclusion that could be drawn from these results is that surgical menopause in itself is a risk 
factor for accelerated cognitive impairment and that E therapy would be particularly indicated 
for this group. However, in another observational study [69], surgically menopausal women 
who had an E2 implant for approximately 10 years had worse long term episodic memory and 
mental flexibility, and more psychological and somatic menopausal symptoms than untreated 
surgically menopausal women. These negative results are in line with other findings of an 
association between better Verbal Fluency and HT use in younger (<58 years) surgically 
menopausal women, but not in older surgically or younger and naturally menopausal women 
[70]. These findings also tie in with an observational study which indicated that former -but 
not current- users of HT were protected against AD [71]. However, interactions of duration of 
use and protective effects were not always found. For example, in another observational study 
[72], surgically menopausal women using HT compared to surgically menopausal women 
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who were not using HT had better verbal memory and constructional abilities at age 65. As 
duration of treatment was not reported in this study, it is possible that the majority of women 
in this study had only used HT for a limited period of time. . 
 
Thus, it must be kept in mind that several clinically important questions are left unanswered, 
such as effect of duration of use and the generalisability of WHIMS to women for whom HT 
is an indication, i.e. perimenopausal women who have menopausal symptoms [73]. While our 
quantitative meta-analyses identified surgical menopausal women as those most effectively 
treated for cognitive deficiency by HT [39], other reviewers suggested that women who were 
highly symptomatic (which would include most of the surgically menopausal women) showed 
largest treatment effects [74]. Although when statistically tested [15], menopausal symptoms 
did not explain improvement on cognitive function, these issues need to be further elucidated. 
There is no doubt that the findings of these trials have had and will continue to have a huge 
influence on the industry and the use of HT. Further, more controlled studies need to be done 
in order to fully understand, support or refute the findings so far. The key to future 
understanding may lie in focusing on interactions of the factors mentioned above and genetic 
risk factors. 
 
      3.        Genetics 
It is possible that an interaction exists between HT and genetic factors. More specifically, the 
effect of HT may depend on a woman’s particular genetic profile. It is has been found that 
having at least one APOE ε4 allele is at least 2-3 times more likely in AD cases [75] Some 
studies found that cognitive decline was prevented with HT, but only in women without the 
ε4 allele [76,77]. However, at least 5 other studies did not find any significant difference 
when taking the APOE genotype into account [7,35,71,78,79].  
We and others, using highly sensitive assays, have found that E2 levels were actually slightly 
elevated in women with AD [19,59]. It could be hypothesized that women with AD have a 
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genetic predisposition to higher E2 levels. Certain genes are involved in the metabolism and 
synthesis of E2. For example, the enzyme cytochrome P450c17a is involved in E synthesis, 
which is regulated by the CYP17 gene. This gene is located on chromosome 10 and has 2 
allele variants. A polymorphism (or variation) of this gene is the A2 allele, which causes an 
increase in the quantity of enzyme produced, resulting in higher E levels. The allele versions 
of this gene without this variation are known as A1. It has been reported by several studies 
that people who are A2 homozygotic (have both A2 gene allele versions: A2:A2) or who are 
heterozygotic (with just one A2 allele: A2:A1) have higher levels of E than people with two 
A1 alleles (A1:A1) [80]. Therefore, using HT to increase the levels of E in women who are 
homozygotic (A2:A2) and already have higher levels of E could have a detrimental effect. It 
is possible that there may be optimal levels of E for the brain to function at the most efficient 
level. Therefore, increasing E2 above this optimal level could result in negative effects on the 
brain. If our review data relating type of treatment to age are correct, possibly this is related to 
different optimal levels of E with age (e.g. lower plasma levels of E2 are reached with CEE 
and transdermal E2 compared to oral and bolus E2, see figure 1). Similar mechanisms have 
been postulated for actions of T in elderly men [19]. Lower levels of E may thus be more 
effective in older women when compared to younger menopausal women, particularly for 
those who already have higher endogenous E levels. 
 
DNA damage has been associated with AD pathology [81]. P450 (CYP) 1B1 is a key enzyme 
in the metabolism of E2. 4-hydroxylation of E2 [regulated by expression of cytochrome P450 
(CYP)] results in a reduction of estrogenic activity. A toxic metabolite, that has been 
associated with DNA damage, is a product of this [82]. The Val432 allele variant is associated 
with higher 4-hydroxy E2 levels than the Leu432 variant. In women who would have high E 
levels, this variant could result in dangerous metabolites, potentially leading to DNA damage 
which could be implicated in AD risk.  
 
 15
Additionally, the inactivation of reactive metabolites, such as catecholestrogens, is regulated 
by Catechol-O-MethyTransferase (COMT), which is regulated by the gene COMT 
(Val108/158) Met). The COMT Met/Met polymorphism may be a risk factor when compared 
with the COMT Val/Val genotype, in that reactive metabolites are not inactivated [83]. If 
women have genotypes CYP17 A2, P450CYP1B1 Val432 and COMT Met/Met and are then 
given HT, they might produce very high levels of toxic metabolites, which might put them at 
risk for dementia. 
 
These theories have not been fully investigated, but may have important implications in our 
knowledge of the causes of AD and need to be substantiated in further studies.  
 
In an observational study from the Mayo Clinic, Minnesota, it was found that women who 
underwent surgical menopause had a 40% increased risk of dementia. Women who had 
bilateral ovariectomy by the age of 46 had a 70% increased risk of dementia. The removal of 
one ovary before 38 years of age resulted in a 260% increase in the risk of dementia [59]. The 
reason for this trend could be due to early exposure to low levels of potentially protective E 
levels. However, life long exposure to E (calculated from age of menopause and onset of 
menses) has shown controversial associations with the onset of dementia [19]. Alternatively, 
surgical menopause and increased risk of dementia may be linked because women usually 
undergo surgical menopause because of endometrial cancer.  The type of genetic risk markers 
mentioned above, leading to high levels of toxic estrogenic metabolites, could be implicated 
in the mechanism explaining the association between endometrial cancer and AD. If this is so, 
other steroid-sensitive cancers, such as breast cancer, could also have a higher incidence in 
women who survive this and then to go onto develop AD.  
 
      4. Conclusion 
The question that needs to be asked is whether oral E2 can have a positive effect on cognitive 
function in recently postmenopausal women for a longer period of time. It is unclear whether 
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this effect pertains to women who have undergone surgical menopause and/or those with 
menopausal symptoms, and whether this effect is mediated by symptom alleviation. As can be 
seen from previous studies, it seems that CEE is not an effective form of HT when addressing 
memory problems in this younger, more recently menopausal group.  
 
It has also previously been stated that the primary reason for a lack of effect of HT on 
menopausal cognitive decline in women is their age. Some believe that there is a critical 
window of time after which HT is ineffective, as it will not only have no effect on cognitive 
decline, but may also result in additional detrimental effect and impair cognition further. 
However, some treatment studies do show positive effects of HT in older women.  Some 
aspects of cognition are possibly more sensitive to these effects than others.  
 
Whether women have undergone natural or surgical menopause may play a crucial role in this 
debate. A sudden and early loss of E may not the most important factor in this association. 
Instead, it is possible that the same genetic predisposition to reasons for having to undergo 
surgical menopause, underlie the increased risk of AD. Especially if women who are 
genetically at risk take HT and increase their levels of endogenous E2, this could potentially 
affect the production of toxic metabolites and lead to DNA damage, which is implicated in a 
variety of age-related morbidity factors, such as some cancers, but also AD. 
 
To conclude, the studies to date suggest that short term (up to 3 months) oral E2 treatment 
(with P for women with an intact uterus) for symptomatic recently natural and surgically 
menopausal women is the most favorable combination to benefit verbal memory but also to 
improve symptoms, the main indication for treating women with E. Whether genetic 
predispositions associated with E metabolism modify a women’s risk for dementia remains to 
be investigated. 
contains 5385 words text 
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      5. Future Perspective 
In a world with constant advances in ways to prolong life and improve standards of living, it 
is evident that the prevalence of age-related disease, such as dementia, is bound to increase. 
This creates not only a higher demand on society’s resources, but also the economy as a 
whole. In a report published by the London School of Economics via the Alzheimer’s 
Research Society, the United Kingdom alone is estimated to be faced with double the costs of 
care for the elderly in the next 30 years. Therefore this is a topic which will have even greater 
significance and importance in the future. 
 
The general confusion and conflicts seen in this area are worrying, particularly for 
postmenopausal women who are plagued by symptoms, such as hot flushes, night sweats and 
mental instability. However, just as history has shown a shift in perspective over the last ten 
years, what the next ten years bring will hopefully result in the clarification of the effects that 
HT has on cognition in menopausal women with and without dementia. The future lies in 
more RCTs which take into consideration all the variables that have been seen to influence 
the impact of HT on cognition. A change in perspective is needed to focus on which variables 
result in a positive effect of HT, instead of just those aspects that may result in negative 
findings. The inclusion and exclusion criteria used in future studies should take into 
consideration such as the influence of age, window of time, treatment form/route, surgical vs. 
natural menopause, and more recently, possibly genetics. 
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6. Executive summary 
Introduction 
• As we age, there is a decline in certain cognitive functions, such as verbal memory, 
complex spatial and verbal skills 
• Cognitive decline with age ranges from ‘successful’ aging to more severe 
deterioration and dementia, of which Alzheimer’s disease (AD) is the most common. 
• Women may be at greater risk of developing AD than men. 
• The fact that women reach an older age than men does not explain this difference in 
dementia prevalence, because age-specific AD incidence is also higher in women. 
• It was theorised that a more severe deficiency in estrogen (E) in elderly women, when 
compared to men after menopause, may increase their risk of AD  
• Hormone therapy (HT) consisting of E has been suggested as a way of 
treating/preventing AD in older women and observational studies have found 
protective associations. 
Historical Background 
• Animal models have shown that estrogen increases dendritic density in the 
hippocampus, and estrogen receptors are highly concentrated in the hippocampus. 
• People with AD have severely affected hippocampal regions, and therefore a lack of 
estrogen in this area may be a precursor for the development of AD. 
• Estrogen may protect against metabolic decline of certain regions susceptible to AD 
in postmenopausal women. 
• The early nineties provided a wealth of research which supported the idea that HT is 
an effective treatment method against AD.  
• However, methodological problems of earlier studies and the opposing results found 
by more recent studies have lead to a change in perspective. 
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Women’s Initiative Memory Study (WHIMS) 
• The WHIMS was a randomized, placebo-controlled trial (RCT) which used 
conjugated equine estrogens (CEE) with medroxyprogesterone (MPA) vs. placebo, or 
continuous unopposed CEE vs. placebo. Both treatments in this study found 
detrimental effects of HT on cognition in postmenopausal women. 
• Some WHIMS researchers advice that the popularly used CEEs, Premarin and 
Prempro, are detrimental to neurocognitive health and therefore do not recommend 
HT as an effective therapy for dementia.  
• There are several possible reasons for the differences reported in results between 
WHIMS, earlier studies and other more recent HT trials. 
Factors explaining the variability in outcomes between studies 
• Age – It is believed by some that women over 65 years of age can not benefit from 
the beneficial effects of HT. However, some studies found positive short lived effects 
of HT in women with dementia 
• ‘Window of Opportunity’ – there may be a critical period of time in which HT is 
effective. This may be in younger, symptomatic recently menopausal women with a 
minimal delay between ovariectomy and HT onset. However, studies suggest that, 
these effects, when found, are only short-lived (up to 2-3 months). 
• Treatment form / route – Conjugated equine estrogens (CEE) is the main treatment 
used in studies that showed no effects of HT on verbal memory, whereas oral and 
bolus injections of estradiol (E2) (alone or combined with progesterone) have yielded 
positive results in recent menopausal women, particularly if they were symptomatic.  
• Orally administered CEEs and transdermal E2 has also been found to be effective in 
older women suggesting that optimal type and treatment route may be modified by 
age. 
• Surgical menopause – Some treatment trials have shown that HT may be most 
effective in women whom have undergone surgical menopause 
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Genetics 
• The effect of HT may depend on a woman’s specific genetic polymorphisms 
associated with E synthesis and metabolism, resulting in higher endogenous E2 levels 
which may be detrimental.  
• DNA damage has been associated with AD onset. 4-hydroxylation of E2 may result 
in a toxic metabolite, which has been associated with DNA damage. Certain genetic 
polymorphisms are associated with higher production or lower break-down of these  
toxic metabolites 
• The genotypes CYP17 A2, P450CYP1B1 Val432/Val and COMT Met/Met in 
combination with HT may increase levels of E2 and toxic metabolites which could 
result in DNA damage and which could put women at risk of AD. 
Conclusion 
• From previous studies, it seems that CEE is not an effective form of HT for cognitive 
complaints in recently menopausal women. E2 has yielded more positive results, with 
or without P  
• It is argued that there is a critical window of time in which women are at the optimal 
age for the beneficial effects seen with HT, after which it is not effective or even 
detrimental. However, other positive treatment studies of older women refute this 
• Positive effects of HT may be seen  particularly in younger, surgical menopausal 
women, using oral E2 as the treatment form and seem to affect some components of 
cognition and not others. Effects are short lived and small, whether they are detected 
in older or younger postmenopausal women. We may need to further investigate the 
genetic make-up of the individual before treating women with HT  
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Future Perspectives 
• There is, and will continue to be, a great demand on societies resources due to the fact 
that we are living longer lives and therefore prevalence of age-related cognitive 
decline is likely to also increase . 
• The confusion seen in the last ten years about the effects of HT in the treatment of 
cognitive decline is worrying. Future studies must take into consideration all the 
variables that have come from the multitude of previous investigations and combine 
knowledge to come to a more concrete foundation 
• Researchers should possibly look carefully at the inclusion criteria of their 
participants and take into consideration the findings that others have shown, such as 
window of time, treatment form/route, surgical vs. natural menopause and also 
genetic factors that may tie all this together. 
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